<DOC>
	<DOCNO>NCT01252667</DOCNO>
	<brief_summary>This phase II trial study side effect well clofarabine work give together low-dose total-body irradiation ( TBI ) treat patient acute myeloid leukemia ( AML ) undergo donor peripheral blood stem cell transplant ( PBSCT ) . Giving chemotherapy TBI donor PBSCT help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet .</brief_summary>
	<brief_title>Clofarabine Low-Dose Total-Body Irradiation Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose clofarabine combination 2 , 3 , 4 Gy TBI preparation hematopoietic cell transplantation ( HCT ) human leukocyte antigen ( HLA ) -identical relate HLA-matched unrelated donor patient AML . ( Part 1 ) II . To determine efficacy maximum tolerate dose clofarabine combine 2 , 3 , 4 Gy TBI reduce 6 month relapse rate patient AML compare historical experience fludarabine 2 Gy TBI . A satisfactory improvement consider 6 month relapse rate decline 35 % 20 % among high-risk ( objective low risk group terminate August 2014 ) . ( Part 2 ) SECONDARY OBJECTIVES : I. Leukemia-free overall survival . II . Non-relapse mortality ( NRM ) &lt; 5 % 100 day . III . Engraftment rate &gt; = 95 % . IV . Prognostic significance cytogenetics genetic marker detect traditional karyotype analysis , special respect tyrosine kinase receptor mutation ( fms-like tyrosine kinase 3 [ FLT3 ] ) , retrovirus-associated deoxyribonucleic acid ( DNA ) sequence ( RAS ) - nucleophosmin gene mutation along CCAAT/enhancer bind protein , alpha ( C/EBP ) mutation . V. Rigorous monitoring minimal residual/recurring disease standard morphologic , flow cytometric , molecular technique order facilitate early intervention . VI . To evaluate pharmacokinetics clofarabine ( pharmacokinetic sample discontinue January 2017 ) . OUTLINE : This dose-escalation study clofarabine . CONDITIONING REGIMEN : Patients receive clofarabine intravenously ( IV ) 2 hour day -6 -2 . Patients also undergo TBI day 0 . IMMUNOSUPPRESSION : Patients related donor receive cyclosporine orally ( PO ) every 12 hour day -3 56 taper day 180 mycophenolate mofetil PO every 12 hour day 0 28 . Patients unrelated donor receive cyclosporine PO every 12 hour day -3 100 taper day 180 mycophenolate mofetil PO every 8 hour day 0 40 taper day 96 . TRANSPLANTATION : Patients undergo allogeneic PBSCT day 0 . After completion study treatment , patient follow 4 month every year thereafter .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Patients age &gt; = 55 year AML OR patient age &lt; 55 year AML , also preexist medical condition prior therapy consider high risk serious toxicity associate conventional , highdose preparative regimen Patients must morphologic leukemiafree state ( marrow blast &lt; 5 % ) without evidence extramedullary disease within 21 day HCT Only patient Relapse Risk Score &gt; 0 ( `` high risk '' ) enrol Part 1 ; patient Relapse Risk Scores enrol Part 2 ( low risk group terminate August 2014 ) HLAidentical relate HLAmatched unrelated donor available A sign informed consent form minor assent form DONOR : FHCRC match allow grade 1.0 2.1 : unrelated donor prospectively : match HLAA , B , C , DRB1 DQB1 high resolution typing ; single allele disparity allow HLAA , B , C define high resolution type DONOR : A positive antidonor cytotoxic crossmatch absolute donor exclusion ; donor exclude preexist immunoreactivity identify would jeopardize donor hematopoietic cell engraftment ; determination base standard practice individual institution ; recommended procedure patient 10 10 HLA allele level ( phenotypic ) match obtain panel reactive antibody ( PRA ) screen class I class II antigens patient HCT ; PRA show &gt; 10 % activity , flow cytometric B T cell cytotoxic cross match obtain ; donor exclude cytotoxic cross match assay positive ; patient HLA Class I allele mismatch , flow cytometric B T cell cytotoxic cross match obtain regardless PRA result DONOR : Patient donor pair homozygous mismatch allele consider twoallele mismatch , i.e. , patient A*0101 donor A*0102 , type mismatch allow DONOR : Peripheral blood stem cell ( PBSC ) permit HSC source protocol AML FrenchAmericanBritish ( FAB ) M3 first complete remission ( CR1 ) Active AML involvement central nervous system ( CNS ) disease refractory intrathecal chemotherapy Presence circulate leukemic blast peripheral blood detect standard morphology Patients human immunodeficiency virus ( HIV ) + ( HIV+ patient register Fred Hutchinson Cancer Research Center [ FHCRC ] offer treatment Protocol 1410 ) Fertile men woman unwilling use contraceptive technique 12 month follow treatment Left ventricular ejection fraction &lt; 35 % ( , unable obtain ejection fraction , shorten fraction &lt; 26 % ) ; ejection fraction require age &gt; 50 year history anthracycline exposure history cardiac disease ; patient shorten fraction &lt; 26 % may enrol approve cardiologist Diffusion capacity lung carbon monoxide ( DLCO ) &lt; 40 % ( correct ) , total lung capacity ( TLC ) &lt; 40 % , forced expiratory volume one second ( FEV1 ) &lt; 40 % and/or receive supplementary continuous oxygen The FHCRC principal investigator ( PI ) study must approve enrollment patient pulmonary nodule Patients clinical laboratory evidence liver disease evaluate cause liver disease , clinical severity term liver function , degree portal hypertension ; patient exclude find fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evince prolongation prothrombin time , ascites related portal hypertension , bridge fibrosis , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL , symptomatic biliary disease Serum creatinine within normal limit specify institutional guideline ; patient serum creatinine &gt; upper limit normal , 24hour creatinine clearance perform equal low limit normal Karnofsky score &lt; 60 Lansky score &lt; 50 Patients poorly control hypertension multiple antihypertensives Females pregnant breastfeeding Patients active nonhematologic malignancy ( except nonmelanoma skin cancer ) nonhematologic malignancy ( except nonmelanoma skin cancer ) render evidence disease , great 20 % chance disease recurrence within five year ; exclusion apply patient nonhematologic malignancy require therapy The addition cytotoxic agent `` cytoreduction '' exception tyrosine kinase inhibitor ( imatinib mesylate ) , cytokine therapy , hydroxyurea , low dose cytarabine , chlorambucil , Rituxan allow within three week initiation condition Fungal infection radiological progression receipt amphotericin B active triazole great 1 month Patients active bacterial fungal infection unresponsive medical therapy DONOR : Marrow donor DONOR : Donors HIVpositive and/or medical condition would result increase risk donor filgrastim ( GCSF ) mobilization PBSC collection DONOR : Identical twin DONOR : Any contraindication administration subcutaneous GCSF dose 16 mg/kg/day 5 consecutive day DONOR : Serious medical psychological illness DONOR : Pregnant lactating female DONOR : Prior malignancy within precede 5 year , exception nonmelanoma skin cancer DONOR : Children &lt; 12 year old</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>